JHP Pharmaceuticals has entered into a manufacturing agreement with an undisclosed pharmaceutical company that has developed proprietary products that provide sustained and localized drug concentration. The agreement is for technical transfer, registration batch manufacture and commercial supply of a unique, late-stage ophthalmic product.
JHP’s manufacturing expertise and cGMP compliance history were critical factors in the selection process. Stuart Hinchen, JHP's president and chief executive officer, remarked, “This important product has critical manufacturing requirements. We have successfully manufactured and filled a number of different products over the past few years, all with unique parameters. Our experience in this area provides our customers with a sound resource as the product moves through launch and commercialization. Our record of cGMP compliance driven by experienced quality and regulatory teams continues to be one of the key reasons customers chose JHP."
JHP is expanding its manufacturing capabilities by introducing a new ophthalmic filling line in order to enhance production effectiveness. This equipment will offer a disposable filling circuit, reduced line losses and broader product handling capabilities, within a restricted access configuration, according to the company. The new filling line is under construction and is expected to be fully operational during the second half of 2014.